Agentix CORP. (AGTX) — SEC Filings

Q: What are the key financial highlights for Agentix CORP.?

Key financial highlights for Agentix CORP. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Agentix CORP.?

Key executives at Agentix CORP. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Agentix CORP. stock?

Risk factors for Agentix CORP. (AGTX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Agentix CORP.?

Forward-looking statements and predictions from Agentix CORP. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Agentix CORP.. Recent 10-Q filing on Nov 20, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Agentix CORP. on SEC EDGAR

Overview

Agentix CORP. (AGTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 20, 2025: Agentix Corp. (AGTX) reported a net loss of $144,107 for the three months ended September 30, 2025, a 58.9% increase from the $90,669 net loss in the same period of 2024. For the six months ended September 30, 2025, the net loss widened to $329,931, up from $241,386 in 2024. Total operating expenses

Sentiment Summary

Across 8 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 4 neutral. The dominant filing sentiment for Agentix CORP. is neutral.

Filing Type Overview

Agentix CORP. (AGTX) has filed 6 10-Q, 2 10-K with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (8)

Agentix's Losses Widen Amid Cash Crunch, Going Concern Doubts Mount — 10-Q · Nov 20, 2025 Risk: high
Agentix Corp. (AGTX) reported a net loss of $144,107 for the three months ended September 30, 2025, a 58.9% increase from the $90,669 net loss in the same perio
Agentix's Losses Widen Amid Soaring R&D, Cash Dwindles to $4,412 — 10-Q · Aug 22, 2025 Risk: high
Agentix Corp. (AGTX) reported a net loss of $185,824 for the three months ended June 30, 2025, an increase from the $150,717 net loss in the same period of 2024
Agentix's Mounting Losses Signal Financial Strain — 10-K · Jul 16, 2025 Risk: high
Agentix Corp. (AGTX) reported a net loss of $433,497 for the fiscal year ended March 31, 2025, a significant increase from the prior year. The company's revenue
Agentix Corp. 10-Q: Assets & Liabilities Balance — 10-Q · Feb 18, 2025 Risk: medium
Agentix Corp. filed its 10-Q for the period ending December 31, 2024. The company reported total assets of $40,066,951 and total liabilities of $40,066,951. A s
Agentix Corp. 10-Q: Assets $40M, Liabilities $433K — 10-Q · Nov 18, 2024 Risk: medium
Agentix Corp. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $40,066,951 and total liabilities of $433,497. A sig
Agentix Corp. Revenue Surges in Q1 FY25 — 10-Q · Sep 25, 2024 Risk: medium
Agentix Corp. filed a 10-Q for the period ending June 30, 2024. The company reported $40,066,951 in revenue for the first quarter of fiscal year 2025, compared
Agentix Corp. Files 2024 10-K, Details Note Interest — 10-K · Aug 30, 2024 Risk: medium
Agentix Corp. filed its 10-K for the fiscal year ending March 31, 2024, reporting on its operations and financial condition. The company, formerly FairWind Ener
Agentix Corp. Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 14, 2024 Risk: medium
Agentix Corp. (AGTX) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Agentix Corp. reported revenue of $40,066,951 for the nine months ended

Risk Profile

Risk Assessment: Of AGTX's 8 recent filings, 3 were flagged as high-risk, 5 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Agentix CORP.'s most recent 10-Q filing (Nov 20, 2025):

Net Income: -$144,107
EPS: -$0.00
Cash Position: $5,601
Total Assets: $5,601

Industry Context

Agentix Corp. operates in a sector that often requires significant R&D investment, leading to high operating expenses and potential for extended periods of unprofitability. The competitive landscape likely demands continuous innovation, putting pressure on companies to fund development activities. However, the current economic climate and investor sentiment towards early-stage or struggling biotech/tech firms can make securing additional capital challenging.

Top Tags

financials (4) · Biotechnology (3) · Net Loss (3) · Clinical Stage (2) · Going Concern (2) · Metabolic Disease (2) · subsequent-event (2) · 10-Q (2) · Cash Flow (1) · SEC Filing (1)

Key Numbers

Cash on hand: $5,601 — as of September 30, 2025, down from $4,477 in March 2025, indicating critically low liquidity.
Net loss for Q3 2025: $144,107 — increased from $90,669 in Q3 2024, showing widening operational losses.
Net loss for six months ended Sept 30, 2025: $329,931 — increased from $241,386 in the prior year, reflecting a growing accumulated deficit.
Accumulated deficit: $6,851,459 — as of September 30, 2025, indicating significant historical losses.
Net cash used in operating activities: $115,367 — for the six months ended September 30, 2025, highlighting negative operational cash flow.
Shares of common stock outstanding: 40,066,951 — as of November 19, 2025, indicating the current share count.
Total operating expenses for Q3 2025: $123,097 — increased from $93,010 in Q3 2024, driven by R&D.
Research and development expenses for Q3 2025: $25,079 — increased from $11,850 in Q3 2024, a 111.6% rise.
Net Loss: $185,824 — for the three months ended June 30, 2025, increased from $150,717 in Q2 2024
Cash on Hand: $4,412 — as of June 30, 2025, down from $4,477 on March 31, 2025
Total Operating Expenses: $200,342 — for the three months ended June 30, 2025, up from $151,305 in Q2 2024
Research and Development Expenses: $100,000 — for the three months ended June 30, 2025, up from $55,501 in Q2 2024
Accumulated Deficit: $6,707,352 — as of June 30, 2025, indicating significant historical losses
Total Current Liabilities: $3,276,178 — as of June 30, 2025, exceeding total assets of $4,412
Accounts Payable - Related Parties: $2,148,663 — as of June 30, 2025, a significant portion of current liabilities

Frequently Asked Questions

What are the latest SEC filings for Agentix CORP. (AGTX)?

Agentix CORP. has 8 recent SEC filings from Feb 2024 to Nov 2025, including 6 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of AGTX filings?

Across 8 filings, the sentiment breakdown is: 1 bullish, 3 bearish, 4 neutral. The dominant sentiment is neutral.

Where can I find Agentix CORP. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Agentix CORP. (AGTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Agentix CORP.?

Key financial highlights from Agentix CORP.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for AGTX?

The investment thesis for AGTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Agentix CORP.?

Executive information for Agentix CORP. is extracted from SEC filings as they are enriched with AI analysis.

What are the main risk factors for Agentix CORP. stock?

Of AGTX's 8 assessed filings, 3 were flagged high-risk, 5 medium-risk, and 0 low-risk.

What are recent predictions and forward guidance from Agentix CORP.?

Forward guidance and predictions for Agentix CORP. are extracted from SEC filings as they are enriched.